LPTH LIGHTPATH TECHNOLOGIES INC Insider Trading

Director Thomas B Ellis sells 3,571,400 LPTH shares at $14.00 (~$50.0M) as stock trades near 52-week high, down -54.9% of pre-tx holdings.

Thomas B Ellis, a Director at LightPath Technologies, sold 3,571,400 shares at $14.00 for a total value of $49,999,600.00, reducing his Table I holdings by -54.9% vs pre-transaction holdings. Notably, this filing involves a derivative-conversion transaction, meaning the shares sold represent a specific batch converted from derivative securities, and the insider's full position reflected in Table II derivatives is not captured in the post-transaction count of 2,934,828 shares. His 5 prior sells at LPTH all produced positive 90-day returns ranging from +21.2% to +30.7%, indicating that at the 90-day mark, those prior sales preceded price appreciation rather than declines — a pattern consistent with his cross-ticker 90d well-timed rate of just 6.25%. The current sale was executed at $14.00, while the stock now trades at $17.62, up +59.2% over the prior 90 days, placing this transaction near the top of the 52-week range of $2.75–$18.94.

Director Thomas B Ellis sold 293,052 shares at blended avg $12.21 for $3,576,837 across 3 days; stock now -26.5% from 52-week high.

Thomas B Ellis executed 3 separate sales totaling 293,052 shares for $3,576,837.00 over a three-day period at prices between $12.16 and $12.29, reducing his holdings by 293,052 shares from 3,283,164 to 2,990,112 shares. The sales occurred as the stock trades -26.5% from its 52-week high of $16.53 and down -15.0% over the prior 30 days, despite the company reporting annual revenue growth of +17.3%. The company reported a negative net income of $-4,106,287.00 in the latest quarter and was unprofitable over its most recent full fiscal year, which provides fundamental context for evaluating the sale. Across his prior 5 trades at LPTH, Ellis's 90-day timing record shows only 1 of 5 sales were well-timed (negative post-sale returns), suggesting limited predictive accuracy at this specific ticker.

LPTH CEO Rubin Shmuel bought 180 shares at $9.70; now trading -35.0% from 52-week high, stock down -10.7% (30d) and -11.8% (90d).

Rubin Shmuel, President & CEO, purchased 180 shares of LIGHTPATH TECHNOLOGIES at $9.70 on 2026-03-27, adding to a holding of 260.8K shares—a modest 0.1% increase in his position. The purchase occurs amid significant headwinds: the stock is trading at $9.31, down 35.0% from its 52-week high and down 10.7% over the past month. Notably, Shmuel's prior two purchases at LPTH in February 2025 both proved poorly timed, with cumulative declines of -14.8% and -10.9% in the 30 days following those trades, and neither position recovered favorably over 90 days. The company is also operating at a loss (net income of $-9.4M on quarterly revenue of $16.4M), which compounds the negative momentum backdrop. The small transaction size ($1.7K total value) and the insider's weak historical timing pattern at this ticker suggest limited conviction behind this purchase.

Director Thomas B Ellis sold 356,909 shares at $12.06–$12.31, netting $4,379,910.54 (derivative conversion)

Thomas B Ellis, a Director at LIGHTPATH TECHNOLOGIES INC, executed 2 separate sales on March 24–25, 2026, totaling 356,909 shares (356.9K shares) for $4,379,910.54 at prices of $12.06 and $12.31. The sales reduced his holdings from 3,640,073 shares to 3,283,164 shares (a 9.8% reduction). This filing is flagged as a derivative-conversion transaction, meaning the underlying securities originated in Table II derivative holdings rather than as a direct share sale, and the insider retains material position in converted form. The substantial dollar value ($4.4M) and the multi-day execution suggest a structured rather than opportunistic liquidation, consistent with a derivative exercise or planned conversion sequence rather than a signal about near-term equity outlook.

Director Thomas B Ellis sells 120,454 shares ($1.4M) across 2 transactions at LPTH; retains 2.90M shares.

Thomas B Ellis, a director at LightPath Technologies, executed 2 separate sales totaling 120,454 shares for $1,446,492.54 at a blended average price of $12.01 on March 17–18, 2026. Post-transaction, Ellis retains 2,900,073 shares, representing a -4.0% reduction from his pre-transaction holding of 3,020,527 shares. The sale is moderate in scale relative to his remaining position, and does not signal a material loss of confidence in the company given the substantial stake he continues to hold.

Director Thomas B Ellis sold 674,995 shares (18.3% of holdings) at avg $12.12 across 3 sales, 2026-03-02 to 2026-03-04, netting $8,180,640.45.

Director Thomas B Ellis executed 3 separate sales totaling 674,995 shares for $8,180,640.45 between March 2–4, 2026, reducing his direct holdings from 3,695,522 shares to 3,020,527 shares. The filing flags a derivative-conversion transaction, indicating that the reported 3.02M post-transaction shares in Table I do not represent his full economic position—additional derivative holdings in Table II (not yet populated in the database) may exist. The sale spans multiple days at prices ranging from $12.03 to $12.18, with a blended average of $12.12. This represents an 18.3% reduction in the direct shareholding reported in this filing, though the true scope of his total position and motivation cannot be fully assessed without visibility into the derivative securities table.

Director Thomas B Ellis sold 300,092 shares (9.2% of holdings) at $12.18 for $3.7M

Thomas B Ellis, a Director, executed a significant sale reducing his stake in LIGHTPATH TECHNOLOGIES INC from 3,255,614 shares to 2,955,522 shares on 2026-02-25 at $12.18 per share, generating $3,655,120.56 in proceeds. The 9.2% reduction in his post-transaction holdings represents a material disposition of his equity position in the company. This substantial share sale merits investor attention given the director's stake size and the volume of shares liquidated, though the rationale for the transaction cannot be determined from the filing alone.

Director Thomas B Ellis sells 733,354 shares (18.4% of holdings) across 4 trades for $9,117,649.90 at $12.43 blended average

Director Thomas B Ellis executed 4 separate sales on LPTH between February 20–24, 2026, totaling 733,354 shares for $9,117,649.90. The blended average price across the transactions is $12.43. Ellis maintains significant holdings with 3,255,514 shares post-transaction. This filing notes a derivative-conversion transaction flag, indicating the Form 4 Table II (derivative securities) contains material position information not yet available in the database—his reported common-share holdings do not represent his total economic stake. The sale represents an 18.4% reduction in his common-share holdings over a five-trading-day period at prices ranging from $12.01 to $13.18.

LPTH CEO Rubin Shmuel buys 1,000 shares at $2.45 on 2025-02-25; stock down -43.4% from 52-week high

CEO Rubin Shmuel purchased 1,000 shares at $2.45 on 2025-02-25, adding to existing holdings of 226,722 shares. The transaction is modest in size (less than 0.4% increase in holdings) and occurs while the stock is -43.4% from its 52-week high and -25.7% over the past 30 days. The company is currently unprofitable with net income of $-2.6M against revenue of $7.4M, and has experienced annual revenue decline of -3.7%. A prior buy at this ticker on 2025-02-19 lacks measurable outcome data, and the CEO's cross-ticker track record shows only 1 prior purchase, limiting the ability to assess any pattern in his trading behavior.

Director Crider buys 1,000 shares of LPTH at $2.51; stock down 42.4% from 52-week high, company unprofitable.

Kimberly Anne Crider, a director, purchased 1,000 shares at $2.51, adding 2.3% to her pre-transaction holdings of 43,796 shares. The purchase occurs in an environment of significant recent price weakness: the stock is currently trading at $2.44, down 42.4% from its 52-week high of $4.24 and down 28.9% over the past 30 days, though up 63.8% over 90 days. The company's fundamentals present headwinds: LPTH posted a net loss of $-2.6M in its most recent quarter, annual revenue contracted 3.7% year-over-year, and the company was unprofitable over the full prior fiscal year. This modest share purchase by a board member does not provide strong conviction signaling given the company's operational challenges and recent sharp equity depreciation.